Induction failure in acute lymphoblastic leukemia of childhood

Cancer

Volumn 85, Issue 6, 1999, Pages 1395-1404

  Silverman, Lewis B ^a,b   Gelber, Richard D ^a   Young, Mary L ^a   Dalton, Virginia Kimball ^a   Barr, Ronald D ^c   Sallan, Stephen E ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Acute lymphoblastic leukemia; Hypoplastic bone marrow; Induction failure; M2 bone marrow; M3 bone marrow; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0033559625     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1395::AID-CNCR25>3.0.CO;2-2     Document Type: Article

References (39)

1. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium protocol 85-01. J Clin Oncol 1994;12:740-7.
2. Reiter A, Schrappe M, Wolf-Dieter L, Hiddeman W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84: 3122-33.
3. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abramowitch M, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment with rotational combination chemotherapy. Lancet 1991;337:61-6.
4. Land VJ, Shuster JJ, Crist WM, Ravindranath Y, Harris MB, Krance RA, et al. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1994; 12:1939-45.
5. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council UKALL X. Lancet 1995;345:143-8.
6. Conter V, Arico M, Valsecchi MG, Rizzari C, Testi AM, Messina C, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. J Clin Oncol 1995;13:2497-502.
7. Tuburgen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group Phase III trial. J Clin Oncol 1993;11:527-37.
8. Asselin BL, Whitin JC, Coppola DJ, Rupp IR, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-6.
9. Schwartz C, Thompson B, Chilton D, Gelber R, Cohen H, Sallan S. Preliminary analysis of DFCI 91-001 steroid window. Proc Am Soc Clin Oncol 1995;14:345.
10. Silverman LB, McLean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ, et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer 1997;80:2285-95.
11. Harnden DG, Klinger HP. An international system for cytogenetic nomenclature. Basel: Karger, 1985.
12. Cox DR. Analysis of binary data. London: Methuen and Co., LTD, 1970.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Greenwood M. The natural duration of cancer. In: Reports on public health and medical subjects. Volume 33. London: Her Majesty's Stationary Office, 1926:1-26.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996;50:163-70.
16. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc (B) 1972;34:187-220.
17. Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a Phase II study. Cancer Treat Rep 1977;61:885-7.
18. Sallan SE, Camitta BM, Cassady JR, Nathan DG, Frei E III. Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. Blood 1978;51:425-33.
19. Ochs J, Rivera GK, Pollock BH, Buchanan GW, Crist W, Freeman AI. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. Cancer 1990;66:1671-7.
20. Giona F, Testi AM, Annino L, Amadori S, Arcese W, Camera A, et al. Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Br J Haematol 1994;86:55-61.
21. Bordigoni P, Vernant JP, Souillet G, Gluckman E, Marininchi D, Milpied N, et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: a cooperative study of the Groupe d'Etude de la Greffe de Moelle Osseuse. J Clin Oncol 1989;7:747-53.
22. Chao NJ, Forman SJ, Schmidt GM, Snyder DS, Amylon MD, Konrad PN, et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood 1991;78:1923-7.
23. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992;80:1090-3.
24. Lange BJ, Raimondi SC, Heerema N, Nowell PC, Minowada J, Steinherz PE, et al. Pediatric leukemia/lymphoma with t(8;14)(q24;q11). leukemia 1992;6:613-8.
25. Fletcher JA, Lynch EA, Kimball VM, Donnelly M, Tantravahi R, Sallan SE. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 1991;77:435-9.
26. Miller DR, Coccia PF, Bleyer WA, Lukens JN, Siegel SE, Sather HN, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol 1989; 1807-15.
27. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990;18:273-9.
28. Rautonen J, Hovi L, Siimes M. Slow disappearance of peripheral blast cells: an independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood 1988;71:989-91.
29. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995;86: 1292-5.
30. Nachman J, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-71.
31. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997;89:2959-65.
32. Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723-9.
33. Brisco MJ, Condon J, Hughes E, Neon S-H, Sykes PJ, Seshadri R, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994;343:196-200.
34. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet 1998;351:550-4.
35. Cave H, van Der Werfften Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998;339:591-8.
36. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 1993;82:1618-25.
37. Dibenedetto SP, Nigro LL, Mayer SP, Rovera G, Schiliro G. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 1997;90: 1226-32.
38. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T-cells. Blood 1997; 90:549-61.
39. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-21.